2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2174

Urinalysis Monitoring In Children With Henoch-Schönlein Purpura: Is It Time To Revise?
Abstract Number: 2719

Urinary Angiostatin As Alternative To Biopsy In lupus Nephritis Patients Among Egyptian
Abstract Number: 2785

Urinary Inflammatory Cells Strongly Reflect the Disease Activity and Renal Function in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Abstract Number: 2824

Urinary Microalbumin Is Associated With Arterial Stiffness In Patients With Rheumatoid Arthritis
Abstract Number: 593

Urinary Prostaglandin D Synthetase As a Biomarker Of Lupus Nephritis Activity: One Year Longitudinal Study
Abstract Number: 2270

US Guided Treat-To-Target Approach In Early RA: Implications For Uncoupling Of Disease Activity and Structural Damage
Abstract Number: 427

US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Abstract Number: 1775

Use Of “Computer-Aided Lung Informatics For Pathology Evaluation and Rating” Software In High-Resolution Computed Tomography In Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease
Abstract Number: 1412

Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Abstract Number: 38

Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Abstract Number: 1500

Use Of B Lymphocyte Stimulator Inhibitor Belimumab May Be Associated With a Decrease In the Serum Concentration Of Endothelial Growth Factor In Patients With Primary Sjögren’s Syndrome
Abstract Number: 2056

Use Of Biologics In Polymyositis and Dermatomyositis – A National Register Study
Abstract Number: 214

Use Of Dual-Energy Computed Tomography In Evaluation Of Axial Gout
Abstract Number: 1186

Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Abstract Number: 2148

Use Of Low Dose Aspirin Is Associated With Reduced Medial Tibial Cartilage Loss In Symptomatic Osteoarthritis: DATA From A Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].